SEC Tracker
Get the app

Dermata Therapeutics DRMA

BREAKING: Dermata’s XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

Form
8-K
Filed
Period
Importance
Notable
Document
8-K
Exhibit 99.1
Press release
  • Makes a Regulation FD disclosure (7.01)
  • Discloses other events (8.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Dermata Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Oragenics OGEN public float $3M, Jun 30, 2025
  2. MetaVia MTVA public float $3M, Jun 30, 2025
  3. Inhibitor Therapeutics INTI public float $3M, Jun 30, 2025
  4. PTC Therapeutics PTCT public float $3M, Jun 30, 2025
  5. Integrated Biopharma INBP public float $3M, Dec 31, 2025